My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
July/August 2015
EDUCATION AND RESOURCES
OFID Offers Special Peer Review Track for Fellows of IDSA (FIDSA)

IDSA’s online only, fully open-access journal, Open Forum Infectious Diseases (OFID), offers a special peer review track for Fellows of IDSA (FIDSAs), which results in faster editorial decisions and publication.  

Fellows of the Society may submit one manuscript per year via this track.  To qualify, the Fellow must be an author of the paper, must select reviewers (who may not be collaborators on the research project) to complete a specific review form, must revise the manuscript based on the reviewers’ comments, and then must submit the revised manuscript with the reviews to the editorial office.  Manuscripts may be sent out for additional peer review, and based on the feedback from all of the reviewers and the judgment of the editorial team, a decision will be made.  While there is not a guarantee of publication, this accelerated track results in quicker decisions. 

Feedback from authors about this track has been extremely positive:

“My collaborators and I were preparing to submit a grant revision to the National Institutes of Health. We were hoping to quickly get some follow-up data into a published manuscript to support the application,” says Ravi Jhaveri, MD, FIDSA, of the University of North Carolina School of Medicine. “I utilized the FIDSA fast track at OFID because I thought the speed of the process would be an advantage. In less than a month from the time we had the paper ready, we had identified reviewers, revised the paper according to their comments, and submitted all documents to OFID. We had our acceptance in less than 4 business days, well ahead of our grant deadline.”

Dr. Jhaveri notes that OFID’s status as an open access journal affiliated with IDSA and Oxford University Press provides the added benefit of exposure to valued colleagues in ID. His article, “Hepatitis C Virus (HCV) Vertical Transmission in 12-Month-Old Infants Born to HCV-Infected Women and Assessment of Maternal Risk Factors,” was published in the spring 2015 issue.

To submit your manuscript, read the instructions to authors and submit online. To submit via the FIDSA track, fill out this form.




< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


PATIENT CARE AND SCIENCE
Guideline on Diagnosis and Management of Vertebral Osteomyelitits Released
CDC Updated Guidelines on Treatment of Sexually Transmitted Diseases
FDA Approves Technivie in Combination with Ribavirin for Treatment of HCV
CLINICAL PRACTICE MANAGEMENT
CMS Issues FAQ Document on ICD-10 Implementation
POLICY AND ADVOCACY
White House Releases Five-Year HIV/AIDS Strategy
21st Century Cures Act Progresses Through Congress
House, Senate Committees Recommend 2016 Funding to Address Antibiotic Resistance
News from CDC: Recognizing the 20th Anniversary of the Emerging Infections Program
NIH Requests Input on its Strategic Plan
IDSA Comments on Criteria for $20 Million CARB Diagnostics Challenge
FDA Proposal Would Yield Better Data on Antibiotics in Meat, Poultry
GLOBAL ID
Science Speaks Covers 8th International AIDS Conference
EDUCATION AND RESOURCES
What Not to Miss at IDWeek 2015
OFID Offers Special Peer Review Track for Fellows of IDSA (FIDSA)
Latest OFID Podcast Features Martin Blaser on the Microbiome
YOU AND YOUR COLLEAGUES
FIDSA Designees Announced: 113 Distinguished Physicians, Scientists Honored
Members on the Move
Member Report
From the President
Setting IDSA’s Course to Lead the Future of ID
TOP STORIES
IDSA Compensation Survey: Take 5 Minutes to Help Us Advocate for You
Take Part in IDSA’s Future: Cast Your Vote in Board Elections
Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.